JP2017511387A5 - - Google Patents

Download PDF

Info

Publication number
JP2017511387A5
JP2017511387A5 JP2017506619A JP2017506619A JP2017511387A5 JP 2017511387 A5 JP2017511387 A5 JP 2017511387A5 JP 2017506619 A JP2017506619 A JP 2017506619A JP 2017506619 A JP2017506619 A JP 2017506619A JP 2017511387 A5 JP2017511387 A5 JP 2017511387A5
Authority
JP
Japan
Prior art keywords
bryostatin
pharmaceutical composition
composition according
once
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017506619A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017511387A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/025821 external-priority patent/WO2015160851A1/en
Publication of JP2017511387A publication Critical patent/JP2017511387A/ja
Publication of JP2017511387A5 publication Critical patent/JP2017511387A5/ja
Pending legal-status Critical Current

Links

JP2017506619A 2014-04-18 2015-04-14 脂質蓄積障害の治療のための方法および組成物 Pending JP2017511387A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461981473P 2014-04-18 2014-04-18
US61/981,473 2014-04-18
US201461987360P 2014-05-01 2014-05-01
US61/987,360 2014-05-01
PCT/US2015/025821 WO2015160851A1 (en) 2014-04-18 2015-04-14 Methods and compositions for treatment of lipid storage disorders

Publications (2)

Publication Number Publication Date
JP2017511387A JP2017511387A (ja) 2017-04-20
JP2017511387A5 true JP2017511387A5 (enExample) 2018-04-12

Family

ID=54321042

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017506619A Pending JP2017511387A (ja) 2014-04-18 2015-04-14 脂質蓄積障害の治療のための方法および組成物

Country Status (9)

Country Link
US (3) US9724328B2 (enExample)
EP (1) EP3131543A4 (enExample)
JP (1) JP2017511387A (enExample)
KR (1) KR20170031653A (enExample)
CN (1) CN107072982A (enExample)
CA (1) CA2946115A1 (enExample)
IL (1) IL248494A0 (enExample)
MX (1) MX2016013680A (enExample)
WO (1) WO2015160851A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018034318A1 (ja) 2016-08-18 2018-02-22 国立大学法人 奈良先端科学技術大学院大学 免疫調節剤
AU2019255739A1 (en) * 2018-04-20 2020-11-12 Biojiva Llc Stabilized polyunsaturated compounds and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7256286B2 (en) 1999-11-30 2007-08-14 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin analogues, synthetic methods and uses
JP2003515601A (ja) 1999-11-30 2003-05-07 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ ブリオスタチンアナログ、合成方法および使用
WO2004004641A2 (en) 2002-07-02 2004-01-15 Blanchette Rockefeller Neurosciences Institute PKC ACTIVATION AS A MEANS FOR ENHANCING sAPPα SECRETION AND IMPROVING COGNITION USING BRYOSTATIN TYPE COMPOUNDS
US8497385B2 (en) 2007-08-31 2013-07-30 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin analogues, synthetic methods and uses
WO2009099563A2 (en) * 2008-02-05 2009-08-13 Blanchette Rockefeller Neurosciences Institute Combination of a nmda receptor channel blocker and a pkc activator for treatment of alzheimer's disease
CA2941035A1 (en) 2008-07-28 2010-02-04 Blanchette Rockefeller Neurosciences Institute Pkc-activating compounds for the treatment of neurodegenerative diseases
US20120156180A1 (en) * 2009-08-10 2012-06-21 The Board Of Trustees Of The University Of Illinois Compositions and methods for the treatment of krabbe and other neurodegenerative diseases
US10821079B2 (en) * 2011-11-13 2020-11-03 Cognitive Research Enterprises, Inc. PKC activators and combinations thereof
WO2015148975A1 (en) * 2014-03-27 2015-10-01 Alkon Daniel L Compositions and methods to treat niemann-pick disease

Similar Documents

Publication Publication Date Title
JP2017518334A5 (enExample)
RU2018114447A (ru) Введение дейтерированных усилителей cftr
JP2014198723A5 (enExample)
JP2018534348A5 (enExample)
JP2013505205A5 (enExample)
FI3936130T3 (fi) Valbenatsiinin annostusohjelma hyperkineettisten liikehäiriöiden hoitoon
HRP20150644T1 (hr) Metoda za lijeäśenje atrijalne fibrilacije
JP2014526503A5 (enExample)
JP2015523407A5 (enExample)
HK1206246A1 (en) Use of high dose laquinimod for treating multiple sclerosis
JP2016511753A5 (enExample)
EA202090984A1 (ru) Диспергируемая в полости рта единица дозирования, содержащая эстетрольный компонент
JP2016530291A5 (enExample)
NZ625592A (en) Compositions and methods for the treatment of hepatic diseases and disorders
JP2015522630A5 (enExample)
JP2015500223A5 (enExample)
JP2015510916A5 (enExample)
JP2012502047A5 (enExample)
JP2018090566A5 (enExample)
JP2017507142A5 (enExample)
JP2009517411A5 (enExample)
JP2014507475A5 (enExample)
JP2010500284A5 (enExample)
HRP20221344T1 (hr) Novi pripravak acetaminofenskog spoja bez nuspojave po jetru
JP2016505050A5 (enExample)